Fig. 7
From: NT1014, a novel biguanide, inhibits ovarian cancer growth in vitro and in vivo
The effect of NT1014 on ovarian tumor growth in the KpB serous ovarian cancer mouse model. Thirty KpB mice were divided into three groups and treated with NT1014 and metformin (oral gavage, 75 mg/kg/day, 6 times/ week) or placebo for 4 weeks. The graph shows weekly tumor volumes for each group (a) and tumor weight after treatment (b). The level of VEGF in NT1014 group was significantly lower than that in control group (c). The changes of Ki67, phos-AKT, phos-AMPK, phos-S6, and MMP9 were assessed by immunohistochemistry in the ovarian cancer tissues. The expression of Ki-67, phos-S6 and MMP9 was significantly reduced and phos-AKT and phos-AMPK was increased in the NT1014 treatment group compared with the control group (d). *p < 0.05 and **p < 0.01